A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)

Trial Profile

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Acronyms PYRAMID
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 09 May 2017 Results (n=5025) assessing long term safety of Adalimumab in patients with moderately and severely active Crohn's disease, presented at the Digestive Disease Week 2017.
    • 04 May 2017 According to an AbbVie media release, data from this trial will be presented at Digestive Disease Week (DDW) 2017.
    • 19 May 2016 Results from this trial will be presented at the Digestive Disease Week (DDW) Annual Meeting 2016, according to an AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top